Baseline characteristics of patients with CGD in the MENA region
| Patients characteristics | Values |
|---|---|
| Number of patients | 322 |
| Male:female | 1.8 |
| Age of disease onset | Mean 20.2 (SD: 54.7) mo, median 6.0 (IQR 2.0–18.0) mo, range 0–53 years |
| Age at diagnosis | Mean 40.1 (SD: 64.4) mo, median 20.0 (IQR: 7.0–48.0) mo, range 0–58 years |
| Age at last follow-up (survival age) | Mean 10.6 (SD 9.0) years, median 8.5 (IQR: 3.0–15.0) years, range 0.3–63.0 years |
| Family history of CGD | 104 (32.3%) |
| Consanguinity | 194 (60.2%) |
| Early diagnosis after birth | 55 (17.1%) |
| Death of a previous sibling | 72 (22.4%) |
| Genetic diagnosis | 98 (30.4%) |
| HSCT | 38 (11.8%) |
| Mortality | 53 (16.5%) |
| BCG vaccine | 278 (86.3%) |
| Survival (10-year) | Overall 77.3% |
| AR-CGD 88.0%, XL-CGD 49.6% |
| Patients characteristics | Values |
|---|---|
| Number of patients | 322 |
| Male:female | 1.8 |
| Age of disease onset | Mean 20.2 (SD: 54.7) mo, median 6.0 (IQR 2.0–18.0) mo, range 0–53 years |
| Age at diagnosis | Mean 40.1 (SD: 64.4) mo, median 20.0 (IQR: 7.0–48.0) mo, range 0–58 years |
| Age at last follow-up (survival age) | Mean 10.6 (SD 9.0) years, median 8.5 (IQR: 3.0–15.0) years, range 0.3–63.0 years |
| Family history of CGD | 104 (32.3%) |
| Consanguinity | 194 (60.2%) |
| Early diagnosis after birth | 55 (17.1%) |
| Death of a previous sibling | 72 (22.4%) |
| Genetic diagnosis | 98 (30.4%) |
| HSCT | 38 (11.8%) |
| Mortality | 53 (16.5%) |
| BCG vaccine | 278 (86.3%) |
| Survival (10-year) | Overall 77.3% |
| AR-CGD 88.0%, XL-CGD 49.6% |
HSCT, hematopoietic stem cell transplantation; AR-CGD, autosomal recessive chronic granulomatous disease; XL-CGD, X-linked chronic granulomatous disease; BCG, bacillus Calmette–Guérin.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.